Press Releases

Investors

Press Releases

 
Press Releases
  Date Title and Summary View
Jan 18, 2018
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock, offered at a price of $5.25 per share, before underwriting discounts. The offering is expected to close on or about January 22,...
Jan 17, 2018
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement. All of the shares in the proposed offering are to be sold by Arro...
Dec 27, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the board of directors elected veteran biotechnology executive William Waddill as an independent director of the company, with a term beginning effective January 1, 2018. It is anticipated that Mr. Waddill will ...
Dec 22, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it filed a regulatory submission to begin a Phase 1/2 study of ARO-HBV, which is being developed as a potentially curative therapy for patients with chronic hepatitis B virus (HBV) infection. Pending approval, ...
Dec 20, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it filed a regulatory submission to begin a first-in-human study of ARO-AAT, a second-generation investigational medicine for the treatment of alpha-1 liver disease that leverages Arrowhead's subcutaneously ...
Dec 18, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 11, 2017, five new employees were awarded "inducement" grants under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The option grants e...
Dec 12, 2017
- Conference Call and Webcast Today at 4:30 p.m. EST PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2017 fourth quarter and year ended September 30, 2017. The company is hosting a conference call at 4:30 p.m...
Dec 6, 2017
— Up to 5.0 log10 reduction in HBsAg observed; data presented at HEP DART 2017 — PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) presented new data from the company's Phase 2 clinical study in patients that received multiple doses of AR...
Dec 5, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Tuesday, December 12, 2017, at 4:30 p.m. EST to discuss its financial results for the 2017 fiscal year ended September 30, 2017. Conference ...
Nov 14, 2017
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the company will make a presentation at the following upcoming event: 29th Annual Piper Jaffray Healthcare Conference - New York, November 28-29, 2017 November 28, 9:30 a...
Page:
1
... NextLast
= add release to Briefcase